Jubilant Ingrevia (JUBLINGREA) Q4 24/25 earnings summary

Executive summary

• Achieved sustained revenue and margin growth in specialty chemicals and nutrition, with Q4 EBITDA margin at 14.7% and profit after tax up 153% year-over-year; board recommended a final dividend of 250% (INR 2.5/share), totaling INR 5/share for FY25 and INR 79.8 crores cash outflow.

• Audited standalone and consolidated financial results for FY25 were approved, with auditors issuing an unmodified opinion; consolidated net profit for FY25 was ₹25,117 lakhs, up from ₹18,289 lakhs in FY24.

• Global specialty chemicals sector shows volume recovery, while commodity segments face volume pressure but prices have stabilized; U.S. tariffs have minimal impact, with only 2.5% of global sales affected, and Indian exports expected to benefit from higher Chinese tariffs.

• Investments were made in renewable energy, with O2 Renewable Energy XVIII Pvt Ltd becoming an associate post the third tranche, supporting green energy initiatives.

Financial highlights

• Q4 revenue: INR 1,051 crores (down from INR 1,071 crores YoY); FY25 consolidated revenue was ₹417,761 lakhs, up from ₹413,580 lakhs in FY24.

• Q4 EBITDA: INR 155 crores, up 54% YoY and 5% sequentially; FY25 EBITDA up 22% to Rs 557 crore.

• Q4 PAT: INR 74 crores, up 153% YoY; FY25 consolidated net profit was ₹25,117 lakhs, up from ₹18,289 lakhs in FY24.

• Net debt as of March 31, 2025: INR 658 crores; net debt-to-EBITDA reduced to 1.18x from 1.36x in previous quarter.

• Net working capital to turnover reduced to 17% (from 18.3% in Q3); working capital days down to 61 from 65.

Outlook and guidance

• Expects sustained growth and improved performance, driven by specialty chemicals and nutrition, with continued cost management and investments in multi-purpose plants, Diketene derivatives, new CDMO projects, and human nutrition portfolio.

• Targeting 15%-20% annual growth in specialty and nutrition segments; aiming for 20% overall company growth to meet Pinnacle 3-4-5 vision by FY30.

• EBITDA growth expected to outpace revenue growth in FY26 due to portfolio shift and cost-saving initiatives.

• Steady-state EBITDA margin guidance: specialty chemicals 22%-25%, nutrition 16%-18%, chemical intermediates 10%-12%; company-wide target 17%-18%+.

• The company aims to meet increasing power demand through green energy, leveraging new investments in renewable energy associates.